marginal zone lymphoma

News

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

News

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.